Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 578 Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents     
LETTER TO EDITOR
Year : 2013  |  Volume : 28  |  Issue : 3  |  Page : 187-188  

Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography


1 Department of Nuclear Medicine and PET/CT,Kovai Medical Centre and Hospital Limited,Coimbatore, India
2 Department of Oncology, Comprehensive Cancer Care Centre,Kovai Medical Centre and Hospital Limited,Coimbatore, India

Date of Web Publication9-Oct-2013

Correspondence Address:
Koramadai Karuppusamy Kamaleshwaran
Department of Nuclear Medicine,PET/CT and Radionuclide Therapy,Comprehensive Cancer Care Centre,Kovai Medical Centre and Hospital Limited, Coimbatore 641 014
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-3919.119520

Rights and Permissions

How to cite this article:
Kamaleshwaran KK, Subramanian PV, Natarajan S, Mohanan V, Shinto AS. Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography. Indian J Nucl Med 2013;28:187-8

How to cite this URL:
Kamaleshwaran KK, Subramanian PV, Natarajan S, Mohanan V, Shinto AS. Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl- Tyr3-octreotide single-photon emission computed tomography/computed tomography. Indian J Nucl Med [serial online] 2013 [cited 2019 Dec 13];28:187-8. Available from: http://www.ijnm.in/text.asp?2013/28/3/187/119520

Sir,

Neuroendocrine tumors (NETs) are neoplasms originating from the neural crest and consequently can be localized in different organs. According to Rufini et al., [1] the presence of neuroamine uptake mechanisms and/or peptide receptors on the cell membrane of these tumors is the basis of the clinical use of specific radiolabeled ligands, both for imaging and therapy. Technetium-99m (Tc-99m)-ethylenediamine-N, N′-diacetic acid (EDDA)-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) is a radiopharmaceutical indicated for the diagnosis of tumors overexpressing somatostatin receptors [2] (sstr2) (especially subtype 2, sstr2), which can be imaged with this radiolabeled ligand. [2] HYNIC-TOC single-photon emission computed tomography/computed tomography (SPECT/CT) improve interpretation and allow precise localization of lesions. [3] We report a case of HYNIC-TOC SPECT/CT useful in detecting bone metastasis near urinary bladder activity.

A 58-year-old male with biopsy proven hepatic metastases from NET was sent for localizing primary lesion and any other sites of metastasis. Whole body planar scintigraphy was performed after intravenous injection of 20 mCi (740 Mbq) of Tc-99m-HYNIC-TOC showed photopenic area in the necrotic liver metastasis and also there were two focal uptakes noted in the upper part of right thigh and other below the bladder [Figure 1]. SPECT/CT of the upper thigh including pelvis was performed, which showed a sclerotic lesion in the neck of right femur and additional lesion noted just below the bladder was localized to sclerotic lesion in left pubis [Figure 2] and [Figure 3].
Figure 1: Whole body technetium-99m-hydrazinonicotinyl-Tyr3-octreotide images showing two focal uptakes, one in the right thigh and other just below bladder (arrows). Furthermore photopenic area noted in the liver lesion suggestive of necrosis

Click here to view
Figure 2: Axial fused single-photon emission computed tomography/computed tomography showing uptake in the neck of right femur and left pubis

Click here to view
Figure 3: Axial computed tomography showing minimal sclerosis in the right femur and left pubis

Click here to view


Sstr2 scintigraphy with In-111-octreotide has been one of the standard procedures for imaging NETs. [4] The limitations of this technique are due to the use of In-111 as the radiolabeler with its limited availability, high cost, medium gamma energy leading to suboptimal image resolution and relatively high radiation burden to the patient. [5] 111In-diethylene triamine pentaacetic acid (DTPA)-octreotide SPECT/CT demonstrates that image fusion is clearly superior to SPECT alone, allowing precise localization of lesions and reducing false-positive results. [6] Guggenberg et al., [7] proved that the high specific tumor uptake, rapid blood clearance and predominantly renal excretion as well as improved image quality, lower radiation dose for the patient and daily availability, make Tc-99m-EDDA-HYNIC-TOC a promising candidate for an alternative to 111In-DTPA-octreotide for NET imaging. Although planar and SPECT/CT scans in NETs are reported, increased resolution of SPECT and addition of CT is confirmatory for bone metastasis.

 
   References Top

1.Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.  Back to cited text no. 1
    
2.Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: A new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318-25.  Back to cited text no. 2
    
3.Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, et al. Image fusion analysis of (99m) Tc-HYNIC-Tyr (3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005;32:1440-51.  Back to cited text no. 3
    
4.Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.  Back to cited text no. 4
    
5.Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: Preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114-9.  Back to cited text no. 5
    
6.Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008;113:1056-67.  Back to cited text no. 6
    
7.Guggenberg EV, Mikolajczak R, Janota B, Riccabona G, Decristoforo C. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. J Pharm Sci 2004;93:2497-506.  Back to cited text no. 7
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed611    
    Printed18    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal